CanniMed Therapeutics' (TSX:CMED)(OTC:CMMDF)(FRA:0GB) Chief Research Officer, Dr. Larry Holbrook recently filed with SEDI concerning his sales of CanniMed shares. Although the shares he sold make up only a small fraction of CanniMed's 22.7 million shares outstanding, it’s a good idea to keep abreast of what insiders are doing in the markets regardless of the transaction size.
Insider Selling by Chief Research Officer, Dr. Larry Holbrook
On July 31st, Dr. Larry Holbrook made seven separate sales of CanniMed Shares:
200 shares sold at $10.11 CAD/per share = $2,022 CAD
100 shares sold at $10.05 CAD/per share = $1,005 CAD
7,200 shares sold at $10.025 CAD/per share = $72,180 CAD
300 shares sold at $10.083 CAD/per share = $3,025 CAD
500 shares sold at $10.08 CAD/per share = $5,040 CAD
600 shares sold at $10.07 CAD/per share = $6,042 CAD
100 shares sold at $10.05 CAD/per share = $1,005 CAD
In total, Dr. Holbrook sold 9,000 shares for gross proceeds of $90,319 CAD (~$71,885 USD) After these sales, Dr. Holbrook beneficially owns 91,000 shares of CMED.
Conclusion
We're working on a marijuana stock profile for CanniMed, so check back soon and be sure to subscribe to our free Canadian licensed producer newsletter to get updates from Canada's 52 ACMPR licensed producers including CanniMed.
Don't be a stranger, connect with The Daily Marijuana Observer on Facebook, Twitter, StockTwits and Instagram!
D/M/O
Disclaimer
Investing in nanocap, microcap, and small cap stocks is highly speculative. The publishers of DailyMarijuanaObserver.com are not registered as Investment Advisors or Broker-Dealers in any jurisdiction whatsoever. The information contained on DailyMarijuanaObserver.com (“this site”) has been prepared solely for informational purposes. Nothing on the site is an offer or solicitation to buy or sell securities. Investors should seek financial advice regarding the appropriateness of investing in any securities mentioned from their financial advisor.
